Orchestra BioMed Holdings Inc. has announced a new infusion of $70 million in strategic capital from Ligand Pharmaceuticals and Medtronic to support its advanced cardiology programs. Under the agreement, Ligand will invest $35 million, receiving a tiered royalty on future sales of Orchestra's AVIM therapy and Virtue SAB, alongside an additional $5 million equity stake. Medtronic, in turn, will invest $10 million in equity and an additional $20 million in a promissory note convertible to prepaid revenue share, contingent on FDA approval of AVIM therapy. The collaboration will also focus on developing AVIM therapy-enabled leadless pacemakers, marking a significant step forward in Orchestra BioMed's efforts to bring innovative cardiovascular solutions to market.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.